Novel Therapeutic Interventions in Treating Patients with COVID-19 Pneumonia, COVID-19 Acute Respiratory Syndrome and Severe COVID-19 Illness and Promising Vaccine Candidates
Abstract
Patients with COVID-19 pneumonia were detected in Wuhan city, China since late December 2019. More and more cases have been identified in other areas outside Wuhan city of China and abroad, particularly in Italy, Iran and other European countries, including the United Kingdom and the United States. Currently, there is no effective treatment for COVID-19-infected patients. Inhibition of pulmonary inflammatory response is hypothesized to be the key to cure the patients with COVID-19 pneumonia. Chloroquine, a potential broad-spectrum antiviral agent found in 2006, can interfere with the virus’s ability to replicate.
Nevertheless, the World Health Organization (WHO) reported that no randomized clinical trials (RCTs) or quasi-experimental studies on the use of chloroquine or hydroxychloroquine on COVID-19 treatment were identified that compared chloroquine to standard care for treatment of COVID-19. There is very low certainty evidence from RCT or quasi-experiment that hydroxychloroquine results in little or no benefit over standard care for treatment of COVID-19. There is also very low certainty evidence of little difference in overall mortality between hydroxychloroquine and standard care. With regards to safety outcomes, there is very certainty evidence that hydroxychloroquine results in more adverse events than standard care. Evidence for other safety outcomes, such as severe adverse events, cardiac arrhythmia, and QT interval prolongation resulting in sudden death was very…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.